Abstract 159P
Background
The claudin18 isoform 2 (CLDN18.2), a member of the tight junction protein family, is a highly selective target for development of novel therapies in various primary malignant tumors. Due to the interference of CLDN18.1, which is highly homologous to CLDN18.2, selection of appropriate antibodies still need to be further identified.
Methods
Expression of CLDN18.2 was evaluated in a total of 66 gastric adenocarcinoma samples by immunohistochemistry(IHC) using the pan-CLDN18 antibodies (clone 43-14A and clone MM02), which recognizes both CLDN18.2 and CLDN18.1, and the CLDN18.2-specific antibody (clone EPR19202-244). The results were further verified by qPCR and CLDN18.1-specific antibody respectively.
Results
The CLDN18.2 expression evaluated by 43-14A and MM02 showed highly consistentat in different eligibility criterions (≥ 2+ membrane staining intensity in ≥ 40% or ≥ 75% of tumor cells) with 95.45% and 90.91% overall percent agreements(OPA) respectively. While EPR19202-244 showed low sensitivity (84.38%) compared with 43-14A, even after readjusting the optimal threshold according to the ROC curve and Youden index. CLDN18, CLDN18.1 and CLDN18.2 mRNAs were further measured via quantative real-time PCR and IHC for CLDN18.1 was applied. It was verified that all those samples determined to be negative for CLDN18.2 by EPR19202-244 but positive for CLDN18 by pan-CLDN18 antibodies should be identified as true positive for CLDN18.2. Table: 159P
Comparison of clone 43-14A, clone MM02, and clone EPR19202-244
43-14A/MM02/EPR19202-244 | |||||||||
+/+/+ | +/+/- | +/-/- | -/+/- | -/-/+ | -/+/+ | -/-/- | Total | ||
Samples | 29 | 7 | 0 | 2 | 2 | 1 | 25 | 66 | |
Samples were verified | 20 | 5 | / | 2 | 1 | 0 | 9 | 37 | |
qPCR | pan-CLDN18 | 19 | 4 | 2 | 0 | / | 1* | ||
CLDN18.2 | 19 | 4 | 2 | 0 | 0 | ||||
CLDN18.1 | 0 | 0 | 0 | 0 | 1* | ||||
IHC | CLDN18.1-specific | 0 | 0 | 0 | 0 | 0 |
Note: ≥2+ intensity in ≥40% tumor cells defined as CLDN18.2-positive for 43-14A and MM02, and ≥2+ ≥25% for EPR19202-24. *:Possibly due to technical differences in qPCR and IHC
Conclusions
Our results clarify the differences between EPR19202-244, 43-14A and MM02, and suggesting a higher sensitivity and specificity of pan-claudin18 antibodies, which should be used for the dectction of CLDN18.2.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
W. Su, H. Lu, Q. Yan, J. Xu, C. Hua, Z. Huang, L. Ruan, C. Zhu: Financial Interests, Personal, Full or part-time Employment: Amoy Diagnostics. All other authors have declared no conflicts of interest.
Resources from the same session
166P - Metabolomic prediction of breast cancer treatment toxicities
Presenter: Max Piffoux
Session: Poster session 01
167P - A tumor immune microenvironment-based model for prediction of everolimus efficacy in premenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Preliminary results from MIRACLE trial
Presenter: Tan Yujing
Session: Poster session 01
168P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: SHRUTI KAHOL
Session: Poster session 01
169P - Integration of metabolomics and transcriptomics to reveal potential biomarkers associated with treatment response of neoadjuvant therapy in HER2+ breast cancer
Presenter: Ningning Zhang
Session: Poster session 01
170P - Clinical significance and functional role of GPR56 (ADGRG1) in breast cancer
Presenter: Haizhu Chen
Session: Poster session 01
172P - T cell-derived circulating DNA and tumour inflammatory microenvironment in EGFR-mutant advanced non-small cell lung cancer: Correlation with the outcome of EGFR TKI treatment
Presenter: Nicha Zungsontiporn
Session: Poster session 01
173P - Expression of programmed death-ligand 1 and EGFR on circulating tumour cells in advanced lung cancer patients
Presenter: Jayant Khandare
Session: Poster session 01
174P - Frequency and prognostic value of circulating tumor cells in cancer of unknown primary
Presenter: Maria Pouyiourou
Session: Poster session 01
175P - Radiomic biomarker of vessel tortuosity for monitoring treatment change: Preliminary findings in prospective evaluation of ECOG-ACRIN EA5163
Presenter: Pushkar Mutha
Session: Poster session 01